MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Cancer Immunotherapy and Biomarkers
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,980 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,980 works in the cohort · of 4,299,418page 1 of 60

Labels cover 12 of 2,980 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,980 of 2,980 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder +21 more
2015· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
6,228
citations
affno abstractunlabeled
The Immune Landscape of Cancer
Vésteinn Thórsson, David L. Gibbs, Scott D. Brown, Denise M. Wolf, Dante S. Bortone, Tai-Hsien Ou Yang +744 more
2018· article· en· Immunity· Medicine
distilled prediction:candidate · noneconsensus · none
6,191
citations
affunlabeled
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle +23 more
2018· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
1,853
citations
affno abstractunlabeled
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof +209 more
2020· article· en· The Lancet· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1,800
citations
fundno affno abstractunlabeled
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautès‐Fridman, Florent Petitprez, Julien Caldéraro, Wolf H. Fridman
2019· review· en· Nature reviews. Cancer· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
1,784
citations
affno abstractunlabeled
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter +14 more
2019· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,681
citations
affno abstractunlabeled
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah B. Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic +4 more
2021· review· en· Nature Reviews Clinical Oncology· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrow+research_integrity+insufficient_payloadconsensus · research_integrity
1,560
citations
afffundno abstractunlabeled
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed Mahmood, Michael G. Fradley, Justine V. Cohen, Anju Nohria, Kerry L. Reynolds, Lucie Heinzerling +14 more
2018· article· en· Journal of the American College of Cardiology· Medicine
distilled prediction:candidate · noneconsensus · none
1,542
citations
venueno affunlabeled
Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini‐Fard, Shadi Hosseini, Habib Sadeghirad +3 more
2022· review· en· Current Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1,280
citations

How this was built: Screen · Findings · About